Publications & Lectures

Here you can find an overview of various publications and selected lectures:

Original papers

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.
Lacouture ME, Dréno B, Ascierto PA, Dummer R, Basset-Seguin N, Fife K, Ernst S, Licitra L, Neves RI, Peris K, Puig S, Sokolof J, Sekulic A, Hauschild A, Kunstfeld R.
Oncologist. 2016 Oct;21(10):1218-1229. Review.

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016.
Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G; ESMO/ASCO Global Curriculum Working Group.

Merkel cell carcinoma: Overall survival after open biopsy versus wide local excision.
Haymerle G, Fochtmann A, Kunstfeld R, Pammer J, Erovic BM.
Head Neck. 2015 Jun 3.

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Jouary T, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Williams S, Fittipaldo A, Xynos I, Hansson J.
Lancet Oncol. 2015 Jun;16(6):729-36

Vemurafenib resistance signature by proteome analysis offers new strategies and rational therapeutic concepts.
Paulitschke V, Berger W, Paulitschke P, Hofstätter E, Knapp B, Dingelmaier-Hovorka R, Födinger D, Jäger W, Szekeres T, Meshcheryakova A, Bileck A, Pirker C, Pehamberger H, Gerner C, Kunstfeld R.
Mol Cancer Ther. 2015 Mar;14(3):757-68

Proteome profiling of keratinocytes transforming to malignancy.
Paulitschke V, Gerner C, Hofstätter E, Mohr T, Mayer RL, Pehamberger H, Kunstfeld R.
Electrophoresis. 2015 Feb;36(4):564-76.

Prognostic significance of lymph node ratio in patients with Merkel cell carcinoma.
Fochtmann A, Haymerle G, Kunstfeld R, Pammer J, Grasl MCh, Erovic BM.
Eur Arch Otorhinolaryngol. 2015 Jul;272(7):1777-83.

Emerging drugs and combination strategies for basal cell carcinoma.
Dreier J, Dummer R, Felderer L, Nägeli M, Gobbi S, Kunstfeld R.
Expert Opin Emerg Drugs. 2014 Sep;19(3):353-65.

Management of Merkel cell carcinoma of unknown primary origin: the Vienna Medical School experience.
Haymerle G, Fochtmann A, Kunstfeld R, Pammer J, Erovic BM.
Eur Arch Otorhinolaryngol. 2015 Feb;272(2):425-9.

Thrombospondin-2 overexpression in the skin of transgenic mice reduces the susceptibility to chemically induced multistep skin carcinogenesis.
Kunstfeld R, Hawighorst T, Streit M, Hong YK, Nguyen L, Brown LF, Detmar M.
J Dermatol Sci. 2014 May;74(2):106-15.

Smoothened inhibitors in the treatment of advanced basal cell carcinomas.
Kunstfeld R.
Curr Opin Oncol. 2014 Mar;26(2):184-95.

Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells.
Paulitschke V, Haudek-Prinz V, Griss J, Berger W, Mohr T, Pehamberger H, Kunstfeld R, Gerner C.
J Proteome Res. 2013 Jul 5;12(7):3264-76

Merkel cell carcinoma: chemotherapy and emerging new therapeutic options.
Desch L, Kunstfeld R.
J Skin Cancer. 2013;2013:327150.

Proteome analysis identified the PPARγ ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction.
Paulitschke V, Gruber S, Hofstätter E, Haudek-Prinz V, Klepeisz P, Schicher N, Jonak C, Petzelbauer P, Pehamberger H, Gerner C, Kunstfeld R.
PLoS One. 2012;7(9):e46103.

A rare case of primary rhabdoid melanoma of the urinary bladder treated with ipilimumab, an anti-CTLA 4 monoclonal antibody.
Schindler K, Schicher N, Kunstfeld R, Pehamberger H, Toepker M, Haitel A, Hoeller C, Harmankaya K.
Melanoma Res. 2012 Aug;22(4):320-5.

Intradermal indocyanine green for in vivo fluorescence laser scanning microscopy of human skin: a pilot study.
Jonak C, Skvara H, Kunstfeld R, Trautinger F, Schmid JA.
PLoS One. 2011;6(8):e23972. doi: 10.1371/journal.pone.0023972. Epub 2011 Aug 31.

The hsp27kD heat shock protein and p38-MAPK signaling are required for regular epidermal differentiation.
Jonak C, Mildner M, Klosner G, Paulitschke V, Kunstfeld R, Pehamberger H, Tschachler E, Trautinger F.
J Dermatol Sci. 2011 Jan;61(1):32-7.

Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin.
Cueni LN, Hegyi I, Shin JW, Albinger-Hegyi A, Gruber S, Kunstfeld R, Moch H, Detmar M.
Am J Pathol. 2010 Aug;177(2):1004-16.

3,3′,4,4′,5,5′-Hexahydroxystilbene Impairs Melanoma Progression in a Metastatic Mouse Model.
Paulitschke V, Schicher N, Szekeres T, Jäger W, Elbling L, Riemer AB, Scheiner O, Trimurtulu G, Venkateswarlu S, Mikula M, Swoboda A, Fiebiger E, Gerner C, Pehamberger H, Kunstfeld R.
J Invest Dermatol. 2009 Dec 3

Erlotinib and bevacizumab have synergistic activity against melanoma.
Schicher N, Paulitschke V, Swoboda A, Kunstfeld R, Loewe R, Pilarski P, Pehamberger H, Hoeller C. Clin Cancer Res. 2009 May 15;15(10):3495-502. 2009 May 15

Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells.
Paulitschke V, Kunstfeld R, Mohr T, Slany A, Micksche M, Drach J, Zielinski C, Pehamberger H, Gerner C.
J Proteome Res. 2009 May;8(5):2501-10.

Reduction of lymphatic vessels in photodamaged human skin.
Kajiya K, Kunstfeld R, Detmar M, Chung JH. J
Dermatol Sci. 2007 Sep;47(3):241-3.

Dimethylfumarate impairs melanoma growth and metastasis.
Robert Loewe, Teresa Valero, Silvia Kremling, Barbara Pratscher, Rainer Kunstfeld, Hubert Pehamberger, Peter Petzelbauer
Cancer Res. 2006 Dec 15;66(24):11888-96. (IF: 7,6)

Prox-1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role of FGF signalling in lymphangiogenesis.
Jay W. Shin, Martin Min, Frederic Larrieu-Lahargue, Xavier Canron, Rainer Kunstfeld, Lynh Nguyen, Janet E. Henderson, Andreas Bikfalvi, Michael Detmar, Young-Kwon Hong
Mol Biol Cell 17(2): 576-84, 2006 (IF: 6,5)

VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis.
Satoshi Hirakawa, Shotha Kodama, Rainer Kunstfeld, Kentaro Kajiya, Lawrence F. Brown, Michael Detmar
J. Experimental Medicine, 201:1089-99, 2005

Induction of cutaneous delayed type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia.
Rainer Kunstfeld, Satoshi Hirakawa, Young-Kwon Hong, Vivien Schacht, Bernhard Lange-Asschenfeldt, Paula Velasco, Charles Lin, Edda Fiebiger, Yan Wu, Daniel Hicklin, Peter Bohlen and Michael Detmar
Blood, 104:1048-57, 2004

VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins.
Young-Kwon Hong, Bernhard Lange-Asschenfeldt, Satoshi Hirakawa, Rainer Kunstfeld, Paula Velasco, Lawrence F. Brown, Peter Bohlen, Donald Senger, Michael Detmar
FASEB Journal 18 (10):1111-3, 2004

MR Imaging of the Her2/neu and 9.2.27 Tumor Antigens using immunospecific contrast Agents.
Martin Funovics, Barbara Kapeller, Christoph Hoeller, Henry Su, Rainer Kunstfeld, Stephan Puig, Karin Macfelda
Magnetic Resonance Imaging 22(6):843-50, 2004

An N-terminal 80-kDa recombinant fragment of human thrombospondin-2 inhibits endothelial cells in vitro and tumor growth and angiogenesis in vivo.
Yun-Hee Noh, Kant Matsuda, , Young-Kwon Hong, Rainer Kunstfeld, Lucia Riccardi, Hajimu Oura, Michael Streit, Michael Detmar
J. Invest. Dermatol, 121:1536-43, 2003

Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a ‘humanized’ SCID mouse model.
Rainer Kunstfeld, Georg Wickenhauser, Uwe Michaelis, Michael Teifel, Wolfgang Umek, Kurt Naujoks, Klaus Wolff, Peter Petzelbauer
J. Invest. Dermatol. 120:476-482, 2003

The prefabricated scapula flap consists of syngeneic bone, connective tissue and a self-assembled epithelial coating.
Rainer Kunstfeld, Peter Petzelbauer, Georg Wickenhauser, Ingrid Schlenz, Klaus Korak, Kurt Vinzenz, Jürgen Holle
Plast. Reconstruct. Surg. 108:1908-14, 2001

The dermis-prelaminated scapula flap for reconstruction of the hard palate and the alveolar ridge: a clinical and histological evaluation.
Ingrid Schlenz, Klaus Korak, Rainer Kunstfeld, Kurt Vinzenz, Hans Plenk, Jürgen Holle
Plast. Reconstruct. Surg. 108:519-24, 2001

Anti HER-2/neu antibody induces apoptosis in HER-2/neu overexpressing breast cancer cells independently from p53 status.
Thomas Brodowicz, Daniela Kandioler-Eckersberger, Sandra Tomek, Carmen Ludwig, Wolfgang Koestler, Michael Hejna, Rainer Kunstfeld, Michael Krainer, Christoph Wiltschke, Christoph C. Zielinski
Br. J. Cancer 85, 1764-70, 2001

Long term results after surgical basal cell carcinoma excision in the eyelid region.
Stefan Pieh, Andreas Kuchlar, Philipp Novak, Rainer Kunstfeld, Gunda Nagel, F J Steinkogler
Br. J. Ophthalmol. 83:85-88, 1999

Peripheral lymph node addressins are expressed on skin endothelial cells.
Sonja Lechleitner, Rainer Kunstfeld, Christine Messeritsch-Fanta, Klaus Wolff, Peter Petzelbauer
J. Invest. Dermatol. 113:410-414, 1999

MCP-1 and MIP-1 are Most Efficient in recruiting T Cells into the Skin In Vivo.
Rainer Kunstfeld, Sonja Lechleitner, Klaus Wolff, Peter Petzelbauer
J. Invest. Dermatol. 111:1040-1044, 1998

HECA-452+ T Cells migrate through Superficial Vascular Plexus but not through Deep Vascular Plexus Endothelium.
Rainer Kunstfeld, Sonja Lechleitner, Marion Gröger, Klaus Wolff, Peter Petzelbauer
J. Invest. Dermatol. 108:343-348, 1997

Human delayed type hypersensitivity reaction in a SCID mouse engrafted with human T cells and autologous skin.
Peter Petzelbauer, Marion Gröger, Rainer Kunstfeld, Elisabeth Petzelbauer, Klaus Wolff
J. Invest. Dermatol. 107:576-581, 1996

Case reports

Carbamazepine-induced DRESS syndrome with recurrent fever and exanthema.
Julia Valencak, Susanna Ortiz-Urda, Elisabeth Heere-Ress, Rainer Kunstfeld, Wolfgang Base
Int. J. Dermatology 43:51-4, 2004

Sucessful treatment of vulvar lichen sclerosus with topical tacrolimus.
Rainer Kunstfeld, Reinhard Kirnbauer, Georg Stingl, Franz Karlhofer
Arch. Dermatol. 139:850-852, 2003

A unique case of a benign angioproliferation combining features of Kaposi’s sarcoma and diffuse dermal angioendotheliomatosis.
Rainer Kunstfeld, Peter Petzelbauer
J. Am. Acad. Dermatology, 45:601-5, 2001

Book contributions

Zielgerichtetet Therapien (Rainer Kunstfeld) in Konservative Therapie des Basalzellkarzinoms sowie des Gorlin-Goltz Syndroms
Hrsg Ralf Gutzmer, UNI MED Verlag Bremen 2013 (1. Auflage), 2015 (2. Auflage)

Endothelium and Skin
Peter Petzelbauer, Marion Groeger, Robert Loewe, Rainer Kunstfeld
Endothelial Biomedicine
Editor: William C. Aird, Cambridge Press, Boston, USA 2005

Angiogenic Diseases of the Skin
Rainer Kunstfeld, Michael Detmar
Encyclopedia of the microvasculature
Hrsg: D.Shepro, R.K.Jain, Academic Press/Elsevier, San Diego, USA, 2004


The influence of fibroblasts on the differentiation of cultured epithelial cells in vitro.
Jürgen Holle, Rainer Kunstfeld
Plast Reconstr. Surg. 114(2):599, 2004


(Selection from more than 150 lectures given)

Vorträge von Dr. Rainer Kunstfeld

24.04.2017, Wien
Informationsveranstaltung der Initiative Leben mit Krebs: „Der Weiße Hautkrebs“

18.04.2017, Buenos Aires
XII International Congress of Dermatology: „Non Melanoma skin cancer- treatment update“

03.03.2017, Kapstadt
Skin Cancer update, First International MWS Educational Symposium: „Merkel Cell Carcinoma“

19.02.2017, Berlin
Update Medikamentöse Tumortherapie, Zertifizierungskurs Dermato-Onkologie: „Was gibt es Neues in Diagnostik und Therapie beim fortgeschrittenen/metastasierten Basalzellkarzinom?“

15.11.2015, Bogota
2nd Colombian Congress of Dermatological Specialties, 9th Colombian Congress of Pediatric Dermatology, and 6th Latin American Congress of Photobiology and Photodermatology “The future of NMSC (Non Melanoma Skin Cancer)” und “Beyond the Scalpel: Systemic Treatment of advanced Basal Cell Carcinoma (BCC)“

06.11.2015, Belgrad
18. Belgrade Dermatology Days Systemic treatment of advanced BCC

16.06.2015, Bukarest
Summer School in Oncology “Updated Oncology 2015″: State of the Art News & Challenging Topics “Melanoma and Non-Melanoma”

21.02.2014, Berlin
Zertifizierungskurs Medikamentöse Tumortherapie in der Dermato-Onkologie der ADO (Arbeitsgemeinschaft Dermatologische Onkologie) “systemische Therapie des fortgeschrittenen Basalozellkarzinoms”

19.07.2013, Hamburg
World Congress of Melanoma „Targeting the hedgehog pathway for the treatment of advanced BCC“ und „Clinical spectrum of BCC“

30.06.2013, Quebec
Annual Meeting of the Canadian Society of Dermatology „Systemic treatment of advanced basalcellcarcinoma“

14.06.2013, Gmunden
Neurologische Fortbildungstage „Herpes Zoster-richtig diagnostizieren und effizient behandeln“

23.05.2013, London
British Society for Dermatological Surgery „My experience in treating advanced BCC“

07.-09.05.2013, Israel
Insgesamt 7 Vorträge in Tel Aviv, (Rambam Medical Center, Ichilov Medical Center, Assuta Medical Center), Haifa, Beer Sheva und Jerusalem (Hadassah University) „Systemic treatment of advanced skin cancer“

03.05.2013, Dresden
Tagung der deutschen dermatologischen Gesellschaft „Neue Chancen für Hautkrebspatienten-was bringen moderne zielgerichtete Therapien“

27.04.2013, Wien
Rathaus „Der weiße Hautkrebs“ im Rahmen des Krebstages 2013

24.04.2013, Innsbruck
Universitätsklinik für Dermatologie „Updates in Non Melanoma Skin Cancer“

18.04.2013, Hannover
Universitätsklinik Hannover „Symposium Dermato-Onkologie- Melanom und Basaliom“

11.04.2013, Dublin
„New treatment horizons in advanced BCC“

19.03.2013, Basel
General Manager Meeting Roche Europe „Klinische Erfahrungen mit dem neuen Hedgehog Inhibitor Vismodegib“

31.01.2013, Frankfurt
„Neue Entwicklungen beim Basalzellkarzinom- ein interdisziplinäres Seminar“

23.01.2013, Wien
Fortbildung für niedergelassene Ärztinnen und Ärzte „Weißer Hautkrebs“

26.11.2012, Wien
Novomatic Forum, Mini Med Studium „Neuer Trend oder die Zukunft in der Medizin? Die personalisierte Medizin“

14.10.2012, Wien
Wiener Dermatologen Abend „Aktinische Keratosen“

06.10.2012, Fuschl bei Salzburg
Schmerzsymposium für Allgemeinmediziner „Herpes Zoster“

28.09.2012, Prag
21. Annual meeting of the EADV „Tranforming the face of advanced basalcellcarcinoma treatment”

19.09.2012, Venedig
42. Anual ESDR Meeting (European Society for Dermatologic Research „New treatment options for early AKs and SCCs“

14.09.2012, Hannover
22. Deutscher Hautkrebskongress „Fortgeschrittene Basalzellkarzinome“

03.-09.06.2012, Grado, Italien
Zwei Vorträge „Die Sonne-Freund und Feind unsrer Haut“ im Rahmen der Akademie der Ärzte-Ärztewoche

12.04.2012, Wien
Ärztekammer, Fortbildung für niedergelassene Ärztinnen und Ärzte “Therapie des Hautkrebs -Was bringt die Zukunft“

07.09.2011, Barcelona
41 Annual ESDR Meeting „Targeted therapy in NMSC“

02.-03.06.2011, Grado
20. Ärztetage, Akademie der Ärzte „Hauttumore“ und „Viruserkrankungen“

05.04.2011, Mistelbach
Mini Med Studium „ Die Sonne Freund und Feind unserer Haut“

08.10.2010, Gmunden
Symposium der Gesellschaft für Hygiene und Mikrobiologie „Intradermale Impfstoffe“

18.06.2010, Athen
6. EADO Kongress (European Association of Dermatologic Oncology) „New treatment approaches in actinic Keratosis and NMSC“

31.05.-02.06.2010, Grado
19. Ärztetage, Akademie der Ärzte „Pigmentierte Hauttumore“, „nicht pigmentierte Hauttumore“ „kutane Lymphome und seltene Hauttumore“

28.11. 2009, Salzburg
Jahrestagung der ÖGDV „Neue Immunmodulatoren“

17.01.2009, Lech am Arlberg
8. Wintertagung für Allgemeinmedizin, ÖGAM „Herpes Zoster“

14.05.2008, Kyoto
International Investigative Dermatology 2008, „Trombosbondin 2 over expression in the skin of transgenic mice reduces the susceptibility to chemicaly induced malignancy“

06.09.2007, Zürich
37. Annual ESDR Meeting Organisation des EADO Symposiums European assosiation of dermato-oncology

08.06.2007, Mondsee bei Salzburg
14. Salzburger Therapie Gespräche der ÖADF „Lymphgefäße und Melanom-eine gefährliche Interaktion“

12.06.2006, Wien
Seminar der Wiener Ärztekammer „Dermatologie in der Praxis“

05.05.2005, Prag
Melanom-Symposium der Universitätsklinik für Dermatologie in Prag “Antiangiogenetische Therapie des malignen Melanom”

09-11.09.2004, Wien
34. Annual Meeting of the ESDR, “VEGF-A play a key role in the induction of chronic skin inflammation and the associated lymphangiogenic response”

30.04.2004, Rhode Island
65. Annual Meeting of the Society for Investigative Dermatology “VEGF-A in used psoriatics skin inflammation and the associated lymphangiogenic response are ameliorated by systemic blockage of VEGF receptor 1 and 2”

30.04-04.05.2003, Miami Beach
International Investigative Dermatology, “Transgenic VEGF overexpression induces enlargement of cutaneous lymphatic vessels that is further enhanced by delayed type hypersensitivity reaction”

29.-30.09.2000, Bregenz
Jahrestagung der Österreichischen Gesellschaft für Plastische, Ästhetische und Rekonstruktive Chirurgie; „Tissue transformation am Beispiel des präfabrizierten Lappen“

07.-10.05.1998, Köln
Joint Meeting ESDR “European Society for Dermatological Research”, SID “Society for Investigative Dermatology”, JSID “Japanese Society for Investigative Dermatology”
“MCP-1 and MIP-1, but not RANTES, SDF-1 or IP-10 induce the migration of human T cells into human skin sites and their action depends on the presence of human endothelium”

23. -24.04.1997, Washington DC
58. Annual Meeting of the Society for Investigative Dermatology, “HECA-452+ T cells migrate through superficial vascular plexus but not through deep vascular plexus endothelium”

24.-26.01.1997, Leipzig
24. Jahrestagung der Arbeitsgemeinschaft für Dermatologische Forschung “HECA-452+ T cells migrate through superficial vascular plexus but not through deep vascular plexus endothelium”